Clinical Trials Logo
  1. Home
  2. Invasive Breast Cancer
  3. NCT06357338
  4. Details
NCT06357338 Clinical Trial

Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma

Invasive Breast Cancer Clinical Trial

Official title:
Differential Expression and Potential Value of c-MYC in Non-invasive and Invasive Mammary Carcinoma

Clinical Trial Details — Status: Enrolling by invitation

Administrative data
NCT number NCT06357338
Other study ID # Soh-Med-24-03-15MS
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date March 19, 2024
Est. completion date April 1, 2026

Study information
Verified date April 2024
Source Sohag University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective observational study to evaluate c-MYC expression in non invasive and invasive mammry carcinoma

Description:

To correlate different levels of c-MYC expressions with variable clinical and pathological parameters of mammary carcinoma (such as patients' ages, tumor grading, staging, laterality, focality and nodal metastasis, co-existing in-situ components). This study will be carried out on archived formalin-fixed and paraffin embedded tissue blocks that were belonged to 70 women with breast lumps.

Recruitment information / eligibility
Status Enrolling by invitation
Enrollment 70
Est. completion date April 1, 2026
Est. primary completion date April 1, 2025
Accepts healthy volunteers
Gender Female
Age group 15 Years and older
Eligibility Inclusion Criteria: Specimens of Modified Radical Mastectomies from breast carcinoma patients Exclusion Criteria: - Cases with insufficient clinical data. - Tissue blocks of destroyed or insufficient material, unfit for diagnosis. - Cases who received pre-operative chemotherapy.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• no intervention
No intervention

Locations
Country Name City State
Egypt Sohag university Sohag

Sponsors (2)
Lead Sponsor Collaborator
Marwa Mahmoud Hassan Qena Oncology Center

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Gao FY, Li XT, Xu K, Wang RT, Guan XX. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal. 2023 Jan 31;21(1):28. doi: 10.1186/s12964-023-01043-1. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary role of c-MYC in breast cancer difference between expression of c-MYC in non invasive and invasive mammary carcinoma 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03595592 - Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer Phase 3
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT06158217 - Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT02773784 - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
Recruiting NCT01509781 - Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Phase 3
Completed NCT04478669 - Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Recruiting NCT04677816 - Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Phase 2
Terminated NCT01934335 - Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Phase 2
Completed NCT00507611 - Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients N/A
Completed NCT00581750 - Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Completed NCT03304171 - Overall Diet Quality and Breast Cancer Risk N/A
Completed NCT03709186 - Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
Terminated NCT03361800 - Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Early Phase 1
Recruiting NCT04648904 - Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer Early Phase 1
Recruiting NCT06328465 - fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases N/A
Active, not recruiting NCT03109522 - Axillary Reverse Mapping (ARM) Technique N/A
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting NCT03497702 - Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer Phase 2